Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine-containing ART Safety Study in Chinese Adults With HIV-1
CTR20231134Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of doravirine, Delstrigo in Human immunodeficiency virus infection type 1, sponsored by Merck & Co.. Started Apr 2023; status: completed.
02
Drugs
doravirineDelstrigo
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on CTR20231134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231134.